LXRX - NASDAQ

Lexicon Pharmaceuticals, Inc.

LXRX·NASDAQ

$1.94

+2.4%

HealthcareBiotechnology

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$859.52M

EPS-0.1400

P/E Ratio-13.82

Earnings Date07/30/2026

lxrx

Sales/Maturities of Investments

Last Annual Value

252.86M

3-Year CAGR

58%

5-Year CAGR

-1%

10-Year CAGR

Adjust for Inflation

Lexicon Pharmaceuticals, Inc. Competitors Analysis of Sales/Maturities of Investments

LXRX · NASDAQ

Company	Sales/Maturities of Investments	CAGR 3Y	CAGR 5Y	CAGR 10Y
Lexicon Pharmaceuticals, Inc. NASDAQ:LXRX	252.86M	13.3%	46.4%	-5.5%
RAPT Therapeutics, Inc. NASDAQ:RAPT	135.04M	-20.3%	9.9%	N/A
Ocugen, Inc. NASDAQ:OCGN	0.00	N/A	N/A	N/A
Neumora Therapeutics, Inc. Common Stock NASDAQ:NMRA	251.17M	12.1%	N/A	N/A
4D Molecular Therapeutics, Inc. NASDAQ:FDMT	350.38M	N/A	133.9%	N/A
Fulcrum Therapeutics, Inc. NASDAQ:FULC	211.25M	10.0%	19.1%	N/A
Compass Therapeutics, Inc. NASDAQ:CMPX	101.28M	-17.8%	N/A	N/A
Gossamer Bio, Inc. NASDAQ:GOSS	383.54M	5.1%	60.3%	N/A
Omeros Corporation NASDAQ:OMER	109.90M	-52.8%	1.9%	6.6%

Lexicon Pharmaceuticals, Inc. Fair Value Envelope

LXRX · NASDAQ

Our analysis suggests that LXRX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.935, this represents a potential HIDDEN relative to our calculated worth for Lexicon Pharmaceuticals, Inc..

HIDDEN

Intrinsic Value

Current Price: $1.935

Related Guides

Blog Categories

Continue your LXRX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.